Cytyc ThinPrep Pap Test Distribution Helps Boost Stock 137% In 1999
This article was originally published in The Gray Sheet
Executive Summary
Increasing availability of Cytyc's ThinPrep Pap test product through added laboratory contracts, coupled with an improved reimbursement environment and strong fundamentals, set the stage for a 137.1% run up of the cervical cytology firm's stock in 1999. The issue closed at 61-1/16, up 35-5/16 for the year.
You may also be interested in...
Candela Gets Lift From Robust Economy, Demand For Aesthetic Procedures
Candela's stock price benefited from three related trends in 1999 - the increased acceptance of the company's flagship aesthetic lasers by physicians, an aging baby boom population willing to pay out-of-pocket for cosmetic surgical procedures, and a booming economy that has made prospective patients feel affluent enough not to give the expense a second thought.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.